Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

查看全文 作　　者：Rafael;Rosell;Enric;Carcereny;Radj;Gervais;Alain;Vergnenegre;Bartomeu;Massuti;Enriqueta;Felip;Ramon;Palmero;Ramon;Garcia-Gomez;Cinta;Pallares;Jose;Miguel;Sanchez;Rut;Porta;Manuel;Cobo;Pilar;Garrido;Flavia;Longo;Teresa;Moran;Amelia;Insa;Filippo;De;Marinis